Zebeta: Advanced Beta-Blocker for Hypertension Control
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.60 | $54.44 (0%) | 🛒 Add to cart |
| 120 | $0.53 | $72.59 $63.52 (12%) | 🛒 Add to cart |
| 180 | $0.44 | $108.89 $78.64 (28%) | 🛒 Add to cart |
| 270 | $0.39 | $163.33 $104.85 (36%) | 🛒 Add to cart |
| 360 | $0.36
Best per pill | $217.77 $129.05 (41%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.54 | $48.39 (0%) | 🛒 Add to cart |
| 120 | $0.46 | $64.53 $55.45 (14%) | 🛒 Add to cart |
| 180 | $0.39 | $96.79 $69.57 (28%) | 🛒 Add to cart |
| 270 | $0.33 | $145.18 $89.73 (38%) | 🛒 Add to cart |
| 360 | $0.31
Best per pill | $193.58 $110.90 (43%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.57 | $51.42 $51.42 (0%) | 🛒 Add to cart |
| 120 | $0.49 | $68.56 $58.48 (15%) | 🛒 Add to cart |
| 180 | $0.41 | $102.84 $73.60 (28%) | 🛒 Add to cart |
| 270 | $0.35 | $154.26 $93.76 (39%) | 🛒 Add to cart |
| 360 | $0.33
Best per pill | $205.67 $117.96 (43%) | 🛒 Add to cart |
Synonyms
| |||
Zebeta (bisoprolol fumarate) is a cardioselective beta-adrenergic blocking agent prescribed for the management of hypertension. It functions by selectively inhibiting beta-1 receptors in the heart, resulting in reduced cardiac output and decreased renin release from the kidneys. This dual mechanism offers a reliable approach to lowering blood pressure with a well-characterized safety profile, making it a trusted choice among cardiologists for long-term cardiovascular risk reduction.
Features
- Active ingredient: Bisoprolol fumarate
- Available in 5 mg and 10 mg oral tablets
- Cardioselective beta-1 adrenergic blockade
- Once-daily dosing regimen
- High oral bioavailability (>80%)
- Hepatic metabolism with renal excretion
- Half-life of 9–12 hours
Benefits
- Effectively lowers systolic and diastolic blood pressure
- Reduces myocardial oxygen demand, beneficial for patients with comorbid angina
- Minimizes risk of stroke, heart attack, and kidney damage associated with uncontrolled hypertension
- Once-daily dosing supports long-term adherence
- Cardioselectivity may reduce incidence of bronchospasm compared to non-selective beta-blockers
- May improve survival outcomes in certain heart failure patients when used as part of a comprehensive regimen
Common use
Zebeta is primarily indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. It may also be used in the management of chronic stable angina pectoris. In some cases, under specialist supervision, it is incorporated into heart failure management protocols to improve ventricular function and clinical stability.
Dosage and direction
The usual initial dose is 5 mg once daily, which may be increased to 10 mg once daily based on individual patient response and tolerability. In elderly patients or those with renal or hepatic impairment, initiation at 2.5 mg daily is recommended. Tablets should be taken with or without food, at the same time each day, and must not be crushed or chewed. Dosage adjustments should occur at intervals of no less than two weeks.
Precautions
Patients should be monitored for signs of worsening heart failure, bradycardia, or hypotension. Use with caution in patients with diabetes, as bisoprolol may mask tachycardia associated with hypoglycemia. Abrupt discontinuation should be avoided due to risk of rebound hypertension or angina exacerbation. Periodic assessment of renal and hepatic function is advised during long-term therapy.
Contraindications
Zebeta is contraindicated in patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, and sick sinus syndrome (unless a permanent pacemaker is present). It should not be used in patients with hypersensitivity to bisoprolol or any component of the formulation.
Possible side effect
Common adverse reactions include fatigue, dizziness, bradycardia, diarrhea, and cold extremities. Less frequently, patients may experience dyspnea, insomnia, rash, or depressive symptoms. Serious side effects such as heart failure exacerbation, bronchospasm, or severe hypotension occur rarely but require immediate medical attention.
Drug interaction
Concurrent use with other beta-blockers, calcium channel blockers (especially verapamil and diltiazem), digoxin, or antiarrhythmics may potentiate bradycardic effects. Concomitant administration with clonidine may exacerbate rebound hypertension upon withdrawal. NSAIDs may diminish the antihypertensive effect of bisoprolol. Insulin and oral hypoglycemics require dosage monitoring due to masked hypoglycemic symptoms.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose is not recommended.
Overdose
Symptoms of overdose include severe bradycardia, hypotension, heart failure, bronchospasm, and hypoglycemia. Management involves gastric lavage if ingestion was recent, followed by supportive measures including atropine for bradycardia, vasopressors for hypotension, and glucagon if necessary. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (20–25°C or 68–77°F) in a tightly closed container, protected from light and moisture. Keep out of reach of children and pets. Dispose of unused medication properly according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Zebeta is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Patients must consult their physician for diagnosis, treatment decisions, and individualized dosing instructions.
Reviews
Clinical studies demonstrate that Zebeta produces significant reductions in both systolic and diastolic blood pressure in approximately 60–70% of patients with mild to moderate hypertension. Long-term extension trials show maintained efficacy over 12–24 months of treatment with generally favorable tolerability. Cardiologists frequently note its predictable pharmacokinetics and once-daily convenience as advantages in hypertension management protocols.